PDF(Pubmed)
Abstract：
UNASSIGNED: Coronavirus disease (COVID-19)-related pneumonia is proposed to be an inflammatory process. The treatment currently includes supportive therapy and low-dose steroids. Anti-inflammatory drugs have been proposed to prevent cytokine storms and improve oxygenation in such cases. The study aimed to assess the efficacy of nebulized lignocaine in COVID-19 patients with pneumonia.
UNASSIGNED: This was an exploratory randomized double-blinded control trial conducted in COVID-19 patients with respiratory failure requiring oxygen therapy either by face mask or non-invasive mechanical ventilation. Patients included were of the age of more than 18 years of either gender. The patients were randomized to receive either lignocaine or distilled water nebulization. The outcomes assessed were PaO2/FiO2 ratio, hemodynamics, respiratory parameters, and sequential organ failure score (SOFA).
UNASSIGNED: The two groups were comparable concerning demographic variables. The PaO2/FiO2 were significantly higher in the lignocaine group from day 2 onward. The SPO2 was significantly higher on day 3 in the lignocaine group and thereafter there was no significant difference. Other hemodynamic, respiratory parameters, and SOFA scores showed no difference in both the groups.
UNASSIGNED: Lignocaine nebulization improved oxygenation in COVID-19 patients and can be used as adjunctive therapy along with other supportive medications.
UNASSIGNED: This was an exploratory randomized double-blinded control trial conducted in COVID-19 patients with respiratory failure requiring oxygen therapy either by face mask or non-invasive mechanical ventilation. Patients included were of the age of more than 18 years of either gender. The patients were randomized to receive either lignocaine or distilled water nebulization. The outcomes assessed were PaO2/FiO2 ratio, hemodynamics, respiratory parameters, and sequential organ failure score (SOFA).
UNASSIGNED: The two groups were comparable concerning demographic variables. The PaO2/FiO2 were significantly higher in the lignocaine group from day 2 onward. The SPO2 was significantly higher on day 3 in the lignocaine group and thereafter there was no significant difference. Other hemodynamic, respiratory parameters, and SOFA scores showed no difference in both the groups.
UNASSIGNED: Lignocaine nebulization improved oxygenation in COVID-19 patients and can be used as adjunctive therapy along with other supportive medications.
摘要：
■冠状病毒病（COVID-19）相关肺炎被认为是一种炎症过程。目前的治疗包括支持治疗和低剂量类固醇。已经提出了在这种情况下预防细胞因子风暴和改善氧合的抗炎药。该研究旨在评估雾化利多卡因对COVID-19肺炎患者的疗效。
■这是一项探索性随机双盲对照试验，在需要面罩或非侵入性机械通气氧疗的COVID-19呼吸衰竭患者中进行。包括的患者的年龄超过18岁，无论性别。患者随机接受利多卡因或蒸馏水雾化治疗。评估的结果是PaO2/FiO2比值，血流动力学,呼吸参数,和序贯器官衰竭评分（SOFA）。
■两组人口统计学变量具有可比性。从第2天开始，利多卡因组的PaO2/FiO2显着升高。利多卡因组的SPO2在第3天显着升高，此后没有显着差异。其他血液动力学，呼吸参数,和SOFA评分在两组中没有差异。
■利多卡因雾化吸入可改善COVID-19患者的氧合，可与其他支持性药物一起用作辅助治疗。
■这是一项探索性随机双盲对照试验，在需要面罩或非侵入性机械通气氧疗的COVID-19呼吸衰竭患者中进行。包括的患者的年龄超过18岁，无论性别。患者随机接受利多卡因或蒸馏水雾化治疗。评估的结果是PaO2/FiO2比值，血流动力学,呼吸参数,和序贯器官衰竭评分（SOFA）。
■两组人口统计学变量具有可比性。从第2天开始，利多卡因组的PaO2/FiO2显着升高。利多卡因组的SPO2在第3天显着升高，此后没有显着差异。其他血液动力学，呼吸参数,和SOFA评分在两组中没有差异。
■利多卡因雾化吸入可改善COVID-19患者的氧合，可与其他支持性药物一起用作辅助治疗。
